Form 8-K - Current report:
SEC Accession No. 0001493152-24-049571
Filing Date
2024-12-11
Accepted
2024-12-11 09:00:19
Documents
17
Period of Report
2024-12-05
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 48938
2 ex99-1.htm EX-99.1 17340
3 ex99-2.htm EX-99.2 26160
4 ex99-1_001.jpg GRAPHIC 4544
5 ex99-2_001.jpg GRAPHIC 3427
  Complete submission text file 0001493152-24-049571.txt   285947

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE pvct-20241205.xsd EX-101.SCH 3027
7 XBRL LABEL FILE pvct-20241205_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE pvct-20241205_pre.xml EX-101.PRE 24173
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3363
Mailing Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929
Business Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929 (866) 594-5999
PROVECTUS BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000315545 (see all company filings)

EIN.: 900031917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36457 | Film No.: 241540290
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)